Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression

Catherine Sharo,Tianhua Zhai,Zuyi Huang

DOI: https://doi.org/10.3390/ph17010137

IF: 4.6

2024-01-21

Pharmaceuticals

Abstract:Alzheimer's disease has become a major public health issue. While extensive research has been conducted in the last few decades, few drugs have been approved by the FDA to treat Alzheimer's disease. There is still an urgent need for understanding the disease pathogenesis, as well as identifying new drug targets for further drug discovery. Alzheimer's disease is known to arise from a build-up of amyloid beta (Aβ) plaques as well as tangles of tau proteins. Along similar lines to Alzheimer's disease, inflammation in the brain is known to stem from the degeneration of tissue and build-up of insoluble materials. A minireview was conducted in this work assessing the genes, proteins, reactions, and pathways that link brain inflammation and Alzheimer's disease. Existing tools in Systems Biology were implemented to build protein interaction networks, mainly for the classical complement pathway and G protein-coupled receptors (GPCRs), to rank the protein targets according to their interactions. The top 10 protein targets were mainly from the classical complement pathway. With the consideration of existing clinical trials and crystal structures, proteins C5AR1 and GARBG1 were identified as the best targets for further drug discovery, through computational approaches like ligand–protein docking techniques.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The paper attempts to address the issue of the inflammatory mechanisms of Alzheimer's disease (AD) and the identification of its potential drug targets. Specifically, the paper focuses on the following points:

1. **Understanding the pathological mechanisms of AD**: Despite extensive research on AD over the past few decades, there are still very few FDA-approved drugs for treating AD. Therefore, there is an urgent need to further understand the pathogenesis of AD and to identify new drug targets.

2. **The role of inflammation in the progression of AD**: AD is closely associated with inflammation in the brain, which is caused by tissue degeneration and the accumulation of insoluble substances. The paper explores how inflammation exacerbates the neurodegenerative progression of AD through the mediation of cytokines and attacks living neural tissue.

3. **Identifying potential drug targets**: The paper constructs protein interaction networks using systems biology tools, particularly the classical complement pathway and G protein-coupled receptors (GPCRs), to identify genes, proteins, reactions, and pathways related to AD and inflammation. Ultimately, the paper screens out the top 10 potential drug targets and evaluates their drug accessibility through existing crystal structures and clinical trial data.

4. **Key proteins studied**: The paper specifically focuses on the proteins C5AR1 and GARBG1, considering them the most promising drug targets. These proteins can be further explored for drug discovery using computational methods such as ligand-protein docking techniques.

In summary, the main goal of the paper is to identify and validate potential drug targets by deeply studying the inflammation mechanisms related to AD, with the aim of providing new ideas and methods for the treatment of AD.